VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 10, 2026
Stock Comparison
Deutsche Boerse AG vs Vertex Pharmaceuticals Incorporated
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Deutsche Boerse AG
DB1 · Xetra
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Deutsche Boerse AG's moat claims, evidence, and risks.
View DB1 analysisVertex Pharmaceuticals Incorporated
VRTX · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.
View VRTX analysisComparison highlights
- Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 81 / 100 for Deutsche Boerse AG).
- Segment focus: Deutsche Boerse AG has 8 segments (28.2% in Securities Services (Clearstream: ICSD/CSD settlement + custody)); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
- Primary market structure: Duopoly vs Quasi-Monopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Deutsche Boerse AG has 12 moat types across 5 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.
Primary market context
Deutsche Boerse AG
Securities Services (Clearstream: ICSD/CSD settlement + custody)
Securities settlement and custody infrastructure (ICSD/CSD) for Eurobonds and domestic markets
Global (Eurobonds + multiple domestic markets)
Custodian banks, broker-dealers, central banks, institutional investors
Settlement/custody infrastructure and asset servicing
28.2%
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
U.S., Europe, Australia, Canada
Patients (via specialty pharmacies/payers); CF care centers
Drug developer/manufacturer
99.9%
Side-by-side metrics
Moat coverage
Shared moat types
Deutsche Boerse AG strengths
Vertex Pharmaceuticals Incorporated strengths
Segment mix
Deutsche Boerse AG segments
Full profile >Financial Derivatives (Eurex trading + Eurex Clearing)
Oligopoly
Commodities (EEX marketplaces + clearing)
Oligopoly
Cash Equities (Xetra + Boerse Frankfurt)
Quasi-Monopoly
FX & Digital Assets (360T + Crypto Finance)
Competitive
Securities Services (Clearstream: ICSD/CSD settlement + custody)
Duopoly
Fund Services (Vestima fund processing + Fund Centre distribution)
Oligopoly
Software Solutions (SimCorp + Axioma Analytics)
Competitive
ESG & Index (ISS STOXX: indices + ESG/governance data)
Oligopoly
Vertex Pharmaceuticals Incorporated segments
Full profile >Cystic Fibrosis CFTR Modulators
Quasi-Monopoly
Hemoglobinopathies Gene Therapy (CASGEVY)
Oligopoly
Acute Pain (JOURNAVX)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.